MA29433B1 - COMPOSES IMIDAZO[1,2-a]PYRIDINYLE INHIBITEURS DU VEGF-R2. - Google Patents

COMPOSES IMIDAZO[1,2-a]PYRIDINYLE INHIBITEURS DU VEGF-R2.

Info

Publication number
MA29433B1
MA29433B1 MA30233A MA30233A MA29433B1 MA 29433 B1 MA29433 B1 MA 29433B1 MA 30233 A MA30233 A MA 30233A MA 30233 A MA30233 A MA 30233A MA 29433 B1 MA29433 B1 MA 29433B1
Authority
MA
Morocco
Prior art keywords
vegf
imidazo
inhibitors
pyridinyl compounds
compounds
Prior art date
Application number
MA30233A
Other languages
English (en)
Inventor
David Anthony Barda
Timothy Paul Burkholder
Joshua Ryan Clayton
Yan Hao
Perry Clark Heath
James Robert Henry
John Monte Knobeloch
David Mendel
Johnathan Alexander Mclean
David Michael Remick
Mark Edward Rempala
Zhao-Qing Wang
Yvonne Yee Mai Yip
Boyu Zhong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA29433B1 publication Critical patent/MA29433B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

LA PRÉSENTE INVENTION CONCERNE COMPOSÉS INHIBITEURS DU VEGF-R2 (RÉCEPTEUR 2 DU FACTEUR DE CROISSANCE DE L'ENDOTHÉLIUM VASCULAIRE) REPRÉSENTÉS PAR LA FORMULE (I). L'INVENTION CONCERNE ÉGALEMENT DES PROCÉDÉS D'UTILISATION DE CES COMPOSÉS.
MA30233A 2005-02-24 2007-09-24 COMPOSES IMIDAZO[1,2-a]PYRIDINYLE INHIBITEURS DU VEGF-R2. MA29433B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65598105P 2005-02-24 2005-02-24

Publications (1)

Publication Number Publication Date
MA29433B1 true MA29433B1 (fr) 2008-05-02

Family

ID=36587138

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30233A MA29433B1 (fr) 2005-02-24 2007-09-24 COMPOSES IMIDAZO[1,2-a]PYRIDINYLE INHIBITEURS DU VEGF-R2.

Country Status (34)

Country Link
US (1) US7666879B2 (fr)
EP (1) EP1904494B1 (fr)
JP (1) JP5055136B2 (fr)
KR (1) KR100904938B1 (fr)
CN (1) CN101128461B (fr)
AR (1) AR056186A1 (fr)
AT (1) ATE490254T1 (fr)
AU (1) AU2006216710B2 (fr)
BR (1) BRPI0609047A2 (fr)
CA (1) CA2599124C (fr)
CR (1) CR9331A (fr)
CY (1) CY1111154T1 (fr)
DE (1) DE602006018615D1 (fr)
DK (1) DK1904494T3 (fr)
DO (1) DOP2006000051A (fr)
EA (1) EA011691B1 (fr)
ES (1) ES2354716T3 (fr)
HK (1) HK1118284A1 (fr)
HR (1) HRP20100677T1 (fr)
IL (1) IL184717A (fr)
MA (1) MA29433B1 (fr)
MX (1) MX2007010326A (fr)
NO (1) NO20074666L (fr)
NZ (2) NZ560402A (fr)
PE (1) PE20061098A1 (fr)
PL (1) PL1904494T3 (fr)
PT (1) PT1904494E (fr)
RS (1) RS51590B (fr)
SI (1) SI1904494T1 (fr)
TN (1) TNSN07323A1 (fr)
TW (1) TW200640924A (fr)
UA (1) UA91535C2 (fr)
WO (1) WO2006091671A1 (fr)
ZA (1) ZA200707136B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009006706A (es) * 2006-12-22 2009-07-02 Astex Therapeutics Ltd Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
JP5442449B2 (ja) * 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
KR20090117950A (ko) 2007-03-08 2009-11-16 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절자 및 그것의 사용 방법
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
US8367662B2 (en) 2007-10-17 2013-02-05 Novartis Ag Organic compounds
GB0810902D0 (en) * 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
WO2010028175A1 (fr) 2008-09-08 2010-03-11 The Board Of Trustees Of The Leland Stanford Junior University Modulateurs de l'activité de l'aldéhyde déshydrogénase et leurs procédés d'utilisation
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
TW201124391A (en) 2009-10-20 2011-07-16 Lundbeck & Co As H 2-substituted-ethynylthiazole derivatives and uses of same
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
AR090566A1 (es) * 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
CN104768548B (zh) 2012-09-28 2018-08-10 范德比尔特大学 作为选择性bmp抑制剂的稠合杂环化合物
BR112015008200A2 (pt) * 2012-11-29 2017-07-04 Hoffmann La Roche derivados de imidazopiridina
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
CN106029660B (zh) 2013-12-16 2019-11-15 阿萨纳生物科技有限责任公司 P2x3和/或p2x2/3化合物和方法
CN103772308B (zh) * 2013-12-31 2015-11-18 北京颖泰嘉和生物科技股份有限公司 5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法
US9988371B2 (en) 2014-06-03 2018-06-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Benzimidazole analogues and related methods
AU2015291522B2 (en) 2014-07-17 2018-12-06 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and pharmaceutical uses thereof
CN104163790B (zh) * 2014-08-19 2016-02-10 贵州威顿晶磷电子材料股份有限公司 一种2-氨基-4-甲基-5溴吡啶的制备工艺
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP2018526452A (ja) 2015-09-03 2018-09-13 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ Ｄｙｒｋ１ａの小分子抑制剤およびその使用
EP3430005B1 (fr) * 2016-03-16 2021-12-08 Plexxikon Inc. Composes et procedes de modulation des kinases, et indications associees
EP3765460A1 (fr) 2018-03-14 2021-01-20 Vanderbilt University Inhibition de la signalisation bmp, composés, compositions et leurs utilisations
US10239885B1 (en) 2018-06-18 2019-03-26 Avista Pharma Solutions, Inc. Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
CA3125350A1 (fr) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibiteurs irreversibles de l'interaction menine-mll
CA3125353A1 (fr) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibiteurs de l'interaction menine-mll
CA3128024A1 (fr) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Composes chimiques
CA3128346A1 (fr) * 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Procede de synthese et nouveaux intermediaires
JP7323218B2 (ja) * 2019-02-18 2023-08-08 深▲チェン▼市塔吉瑞生物医薬有限公司 置換された縮合芳香環誘導体、その組成物、およびそれらの使用
EP3990457A4 (fr) * 2019-06-25 2023-09-13 Sinopsee Therapeutics Composés pour le traitement de troubles oculaires
CN112778294A (zh) * 2021-01-07 2021-05-11 苏州安睿药业有限公司 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000506880A (ja) 1996-03-15 2000-06-06 ゼネカ・リミテッド シンノリン誘導体及びその使用
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
MXPA02000314A (es) 1999-07-09 2004-06-22 Boehringer Ingelheim Pharma Proceso novedoso para la sintesis de compuestos de urea substituidos con heteroarilo.
US6492529B1 (en) * 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
CA2453147A1 (fr) 2001-07-11 2003-01-23 Boehringer Ingelheim Pharmaceuticals, Inc. Methodes permettant de traiter des maladies induites par les cytokines
JP2003313126A (ja) * 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
EP1503757B1 (fr) * 2002-05-02 2007-12-19 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
US7550470B2 (en) * 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
US7262199B2 (en) * 2002-12-11 2007-08-28 Merck & Co., Inc. Tyrosine kinase inhibitors
CN100418965C (zh) 2003-08-15 2008-09-17 万有制药株式会社 咪唑并吡啶衍生物

Also Published As

Publication number Publication date
CN101128461A (zh) 2008-02-20
DE602006018615D1 (de) 2011-01-13
TNSN07323A1 (en) 2008-12-31
JP5055136B2 (ja) 2012-10-24
CA2599124C (fr) 2013-08-06
KR20070099029A (ko) 2007-10-08
AU2006216710B2 (en) 2011-08-11
HK1118284A1 (en) 2009-02-06
EP1904494B1 (fr) 2010-12-01
PT1904494E (pt) 2010-12-23
NZ584753A (en) 2011-06-30
UA91535C2 (en) 2010-08-10
CY1111154T1 (el) 2015-06-11
WO2006091671A1 (fr) 2006-08-31
ATE490254T1 (de) 2010-12-15
NO20074666L (no) 2007-11-09
CR9331A (es) 2008-03-31
KR100904938B1 (ko) 2009-06-29
CN101128461B (zh) 2010-12-22
RS51590B (en) 2011-08-31
MX2007010326A (es) 2007-10-16
EA011691B1 (ru) 2009-04-28
AU2006216710A1 (en) 2006-08-31
DK1904494T3 (da) 2011-02-21
BRPI0609047A2 (pt) 2010-11-16
JP2008531574A (ja) 2008-08-14
ES2354716T3 (es) 2011-03-17
HRP20100677T1 (hr) 2011-01-31
DOP2006000051A (es) 2006-08-31
AR056186A1 (es) 2007-09-26
EP1904494A1 (fr) 2008-04-02
US20090227622A1 (en) 2009-09-10
CA2599124A1 (fr) 2006-08-31
PL1904494T3 (pl) 2011-04-29
EA200701802A1 (ru) 2008-02-28
US7666879B2 (en) 2010-02-23
TW200640924A (en) 2006-12-01
IL184717A (en) 2011-11-30
IL184717A0 (en) 2007-12-03
NZ560402A (en) 2010-06-25
ZA200707136B (en) 2008-11-26
PE20061098A1 (es) 2006-10-20
SI1904494T1 (sl) 2011-02-28

Similar Documents

Publication Publication Date Title
MA29433B1 (fr) COMPOSES IMIDAZO[1,2-a]PYRIDINYLE INHIBITEURS DU VEGF-R2.
TW200612958A (en) Substituted imidazole derivatives
WO2006049835A3 (fr) Derives d'indole et de benzimidazole
MA30531B1 (fr) Anticorps anti-dll4 et leurs procedes d'utilisation
WO2008027812A3 (fr) Dérivés d'imidazopyridine et d'imidazopyrimidine
ZA200807274B (en) Novel pyridine derivatives
TW200642683A (en) Heterocyclic compound
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
TN2009000085A1 (fr) Derives de pyrido (2,3-d) pyrimidinone et leur utilisation comme inhibiteurs de pi3
TW200744593A (en) Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
MXPA04008613A (es) N-aminoacetil-pirrolidina-2-carbonitrilos y su uso como inhibidores de ddp-iv.
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005021536A3 (fr) Nouveaux composes
WO2006116733A3 (fr) Inhibiteurs des proteines kinases
MX2007005611A (es) Compuestos de imidazo[1,2-a]piridina, composiciones, usos y metodos relacionados.
WO2007146124A3 (fr) Inhibiteurs de pde5 substitué
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
WO2008086122A3 (fr) Dérivés cyclisés en tant qu'inhibiteurs d'eg-5
WO2007017728A3 (fr) Nouveaux composes heterocycliques
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
UA97256C2 (ru) Замещенные пиразолы и триазолы как ингибиторы кбв (кинезин-белок веретена)
MA30707B1 (fr) DERIVES D'ISOSERINE DESTINES A ETRE UTILISES COMME INHIBITEURS DU FACTEUR DE COAGULATION Ixa.
PL1831191T3 (pl) Pochodne chromanu i ich zastosowanie jako ligandów receptorów 5-HT
RS50781B (sr) Derivati pirido (2,3-d) pirimidina, njihovo dobijanje, njihova primena u terapiji